Merola, Joseph F.
McInnes, Iain B.
Deodhar, Atul A.
Dey, Amit K.
Adamstein, Nicholas H.
Quebe-Fehling, Erhard
Aassi, Maher
Peine, Michael
Mehta, Nehal N.
Funding for this research was provided by:
Novartis Pharma AG
Article History
Received: 10 December 2021
Accepted: 14 February 2022
First Online: 19 March 2022
Funding
: This study and journal’s Rapid Service Fee were funded by Novartis Pharma, AG.
: All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.
: All authors were involved in the drafting and critical review of the manuscript. JF Merola, IB McInnes, AA Deodhar, AK Dey, N Adamstein participated as investigators of individual studies. M Aassi, M Peine and NN Mehta were involved in the conception/design of this study. E Quebe-Fehling was involved in the analysis of the data in the manuscript. All authors were involved in the interpretation of data in the manuscript.
: Amit K Dey and Nicholas Adamstein: Nothing to disclose. Joseph F Merola: Consultant and/or investigator for Amgen, Bristol-Myers Squibb, AbbVie, Dermavant, Eli Lilly, Novartis, Janssen, UCB, Sanofi, Regeneron, Sun Pharma, Biogen, Pfizer and Leo Pharma. Iain B McInnes: Research grants, consultation fees, or speaker honoraria: AstraZeneca, AbbVie, Amgen, BMS, Cabaletta, Celgene, Evelo, Janssen, Lilly, Novartis, Pfizer and UCB. Atul A Deodhar: Consultant for: AbbVie, Amgen, Aurinia, Bristol Myers Squibb, Celgene, Eli Lilly, GlaxoSmithKline, Janssen, MoonLake, Novartis, Pfizer, UCB, Grant/research support from: AbbVie, Eli Lilly, GlaxoSmithKline, Novartis, Pfizer, UCB. Erhard Quebe-Fehling, Maher Aassi, and Michael Peine: Employee of Novartis with Novartis stocks. Nehal N Mehta: Employee of the US government, grants from Janssen, AbbVie, Celgene, and Novartis for IIS.
: All studies were conducted in accordance with the Declaration of Helsinki and the International Conference on Harmonization Guidelines for Good Clinical Practice. All studies were approved by all competent ethics committees and regulatory authorities. Informed consent was obtained by investigators from all patients enrolled into these studies.
: The datasets generated during and/or analyzed during the current study are not publicly available due to their scope (i.e., the datasets of 19 Novartis-sponsored clinical studies across three indications were analyzed).